What to Expect in 2024: Important Health Economics and Outcomes Research (HEOR) Trends

References

• Shafrin J, Lakdawalla DN, Doshi JA, et al. A strategy for value-based drug pricing under the inflation reduction act. Health Affairs. 2023. doi:10.1377/forefront.20230503.153705
   Google Scholar
• Institute for Clinical and Economic Review (ICER). Cost-Effectiveness, the QALY, and the evLYG. Available from: https://icer.org/our-approach/methods-process/cost-effectiveness-the-qaly-and-the-evlyg/. Accessed December 11, 2023.
   Google Scholar
• Lakdawalla DN, Phelps CE. Health Technology Assessment With Diminishing Returns to Health: the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach. Value Health. 2020;24(2):244–249. doi:10.1016/j.jval.2020.10.003
   Web of Science ®Google Scholar
• Lakdawalla DN, Phelps CE. (GRACE) Model for Measuring the Value of Gains in Health: an Exact Formulation. J Benefit Cost Analysis. 2023;141:44–67. doi:10.1017/bca.2023.6
   Web of Science ®Google Scholar
• Marsh K, van Til JA, Molsen-David E, et al. Health Preference Research in Europe: a Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group. Value Health. 2020;23(7):831–841. doi:10.1016/j.jval.2019.11.009
   PubMed Web of Science ®Google Scholar
• Bouvy JC, Cowie L, Lovett R, Morrison D, Livingstone H, Crabb N. Use of Patient Preference Studies in HTA Decision Making: a NICE Perspective. Patient. 2020;13(2):145–149. doi:10.1007/s40271-019-00408-4
   PubMedGoogle Scholar
• Shiozawa A, Thurston RC, Cook E, et al. Assessment of women’s treatment preferences for vasomotor symptoms due to menopause. Exp Rev Pharm Outcomes Res. 2023;23(10):1117–1128. doi:10.1080/14737167.2023.2250916
   Google Scholar
• Böger S, van Bergen I, Beaudart C, Cheung KL, Hiligsmann M. Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment. Exp Rev Pharm Outcomes Res. 2023;23(8):921–931. doi:10.1080/14737167.2023.2223983
   Google Scholar
• Willems D, Sayed CJ, Van der Zee HH, et al. A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States. J Med Economics. 2023;26(1):503–508. doi:10.1080/13696998.2023.2194804
   PubMed Web of Science ®Google Scholar
• FDA 2023a. Available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence. Accessed October 5, 2023.
   Google Scholar
• FDA 2023b. Available from: https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-artificial-intelligence. Accessed October 7, 2023.
   Google Scholar
• Arlett P, Kjær J, Broich K, Cooke E. Real‐World Evidence in EU Medicines Regulation: enabling Use and Establishing Value. Clin Pharmacol Ther. 2022;111(1):21–23. doi:10.1002/cpt.2479
   PubMed Web of Science ®Google Scholar
• Sarri G. Can Real-World Evidence Help Restore Decades of Health Inequalities by Informing Health Care Decision-Making? Certainly, and Here is How. Front Pharmacol. 2022;13(905820). doi:10.3389/fpharm.2022.905820
   PubMedGoogle Scholar
• World Health Organisation. Health equity. Available from: https://www.who.int/health-topics/health-equity#tab=tab_1. Accessed December 11, 2023.
   Google Scholar
• Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344–2350. doi:10.1001/jama.291.19.2344
   PubMed Web of Science ®Google Scholar
• Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224–2232. doi:10.1056/NEJMsa030954
   PubMed Web of Science ®Google Scholar
• Franklin JM, Lin KJ, Gatto NM, Rassen JA, Glynn RJ, Schneeweiss S. Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. Clin Pharmacol Ther. 2021;109(4):816–828. doi:10.1002/cpt.2185
   PubMed Web of Science ®Google Scholar
• Love-Koh J, Cookson R, Gutacker N, Patton T, Griffin S. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies. Value Health. 2019;22(5):518–526. doi:10.1016/j.jval.2019.03.006
   PubMed Web of Science ®Google Scholar
• Roldos MI, Breen N. Using Economic Evaluation to Hasten Equity. Health Equity. 2021;5(1):627–632. doi:10.1089/heq.2021.0010
   PubMedGoogle Scholar
• World Health Organisations. WHO Model List of Essential Medicines - 23rd list, 2023. Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02. Accessed October 12, 2023.
   Google Scholar
• WHO Model List of Essential Medicines for Children - 9th list, 2023. Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.03. Accessed October 12, 2023.
   Google Scholar
• Daems R. Medicines for the Developing World: Innovation and Economic Policy. Maastricht, The Netherlands: Universitaire Pers Maastricht; 2008. doi:10.26481/dis.20081128rd
   Google Scholar
• Abraham I 1 billion people can access biosimilars; what about the other 7 billion? Center for Biosimilars. Available from: https://www.centerforbiosimilars.com/view/dr-ivo-abraham-column-1-billion-people-can-access-biosimilars-what-about-the-other-7-billion-. Accessed October 12, 2023.
   Google Scholar
• Saleh M, Halloush SS, Rashdan O, et al. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan. J Med Economics. 2023;26(1):835–842. doi:10.1080/13696998.2023.2226007
   PubMed Web of Science ®Google Scholar
• Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I. The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Exp Rev Pharm Outcomes Res. 2023;23(3):309–316. doi:10.1080/14737167.2023.2169135
   Google Scholar
• Diakite I, Nguyen S, Sabale U, et al. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases. J Med Economics. 2023;26(1):1085–1098. doi:10.1080/13696998.2023.2250194
   PubMed Web of Science ®Google Scholar
• Al-Omar HA, Aljehani N, Alshehri A, et al. Ten-year cost-consequence analysis of weight loss on obesity-related outcomes in privately insured adults with obesity in Saudi Arabia. J Med Economics. 2023;26(1):802–810. doi:10.1080/13696998.2023.2221570
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Chapman RH, Pearson SD. Evaluating and Valuing Drugs for Rare Conditions: no Easy Answers. Value Health. 2018;21(5):547–552. doi:10.1016/j.jval.2018.01.008
   PubMed Web of Science ®Google Scholar
• Adkins EM, Nicholson L, Floyd D, Ratcliffe M, Chevrou-Severac H. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category? Clinicoecon Outcomes Res. 2017;9:327–342. doi:10.2147/CEOR.S134230
   PubMed Web of Science ®Google Scholar
• CDER Continues to Advance Rare Disease Drug Development with New Efforts, FDA.gov, 2023. Available from: https://www.fda.gov/drugs/news-events-human-drugs/cder-continues-advance-rare-disease-drug-development-new-efforts-including-accelerating-rare-disease. Accessed December 8, 2023.
   Google Scholar
• Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98(11):829–836. doi:10.1093/qjmed/hci128
   PubMed Web of Science ®Google Scholar
• Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions-A systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18(6):906–914. doi:10.1016/j.jval.2015.05.008
   PubMed Web of Science ®Google Scholar
• Takami A, Kato M, Deguchi H, Igarashi A. Value elements and methods of value-based pricing for drugs in Japan: a systematic review. Exp Rev Pharm Outcomes Res. 2023;23(7):749–759. doi:10.1080/14737167.2023.2223984
   Google Scholar
• Makin C, Neumann P, Peschin S, Goldman D. Modelling the value of innovative treatments for Alzheimer’s disease in the United States. J Med Economics. 2021;24(1):764–769. doi:10.1080/13696998.2021.1927747
   PubMed Web of Science ®Google Scholar
• Alkhatib NS, Abraham I. The six Delta platform for outcome-based contracting for pharmaceuticals. J Med Economics. 2020;23(11):1209–1214. doi:10.1080/13696998.2020.1824161
   PubMed Web of Science ®Google Scholar
• Alkhatib NS, McBride A, Slack M, et al. Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs). J Med Economics. 2020;23(11):1266–1272. doi:10.1080/13696998.2020.1815031
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review (ICER). ICER home page. Available from: https://icer.org/. Accessed December 11, 2023.
   Google Scholar
• DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Ann Intern Med. 2022;175(9):1298–1304. doi:10.7326/M22-1460
   PubMed Web of Science ®Google Scholar
• EudraCT. Welcome to the EudraCT public home page. Available from: https://eudract.ema.europa.eu/. Accessed December 11, 2023.
   Google Scholar
• Centers for Disease Control and Prevention. NHANES Questionnaires, Datasets, and Related Documentation. Available from: https://wwwn.cdc.gov/nchs/nhanes/default.aspx. Accessed December 11, 2023.
   Google Scholar
• AWS Data Exchange. MIMIC-III (‘Medical Information Mart for Intensive Care’). Available from: https://registry.opendata.aws/mimiciii/. Accessed December 11, 2023.
   Google Scholar
• Citrome L. Meta-analyses: editor’s dream or nightmare? Int J Clin Pract. 2013;67(11):1069–1070. doi:10.1111/ijcp.12324
   PubMed Web of Science ®Google Scholar